Suzanne Elvidge has been involved in biopharma science and business publishing and journalism for over twenty years. She became the editor of FierceBiomarkers in November 2011, and has also written for FierceVaccines and FierceDrugDelivery. As a freelance writer she has written news and features for a range of online and print publications including European Life Science, the Journal of Life Sciences (now the Burrill Report), In Vivo, Life Science Leader, Nature Biotechnology, PR Week and Start-Up. She is also the editor of Genome Engineering, a blog that monitors the latest developments in genome engineering. She lives in the Peak District, in a very rural part of Derbyshire, U.K., with her second-hand bookseller husband and two second-hand cats. She can be reached at firstname.lastname@example.org. Follow @suzannewriter on Twitter.
This FierceVaccines special report spotlights 10 promising therapeutic vaccines on their way through clinical development that might just change the face of cancer treatment. Many of them are in the early steps of R&D, so it may be a while, especially for those that are first-in-class, or that are bringing a new technology to the table, but they could be the first baby steps to a brave new world. Click here to check out the full report >>
In Sweden, between 1984 and 1996, there was a four-fold increase in cases of celiac disease, and the rates then fell as quickly as they rose. A team of Swedish researchers looked at medical records to unpack whether there really was a cause and effect between changes in the vaccination patterns and the spike in disease.
Researchers from University of Texas Medical Branch are developing an improved vaccine against Rift Valley fever virus that could make an impact against this growing disease.
The Scottish authorities put a vaccination program in place for pandemic H1N1 2009 (swine flu) in October 2009, and a team of Scottish researchers have assessed its effectiveness in a paper published in The Lancet Infectious Diseases.
Caused by a mosquito-transmitted virus, dengue fever or breakbone fever symptoms include fever, headache, joint, muscle and bone pain, and can occasionally be fatal. BioDiem has signed a global licensing agreement with Australian National University to develop a vaccine technology targeting the dengue virus.
According to news reports, Cuba has eliminated viral hepatitis in its population under 15 through use of a vaccine against hepatitis B developed in Havana.
The European Medicines Agency (EMA) has adopted a positive opinion for Sanofi Pasteur's hexavalent vaccine for babies and toddlers, Hexaxim, as part of a procedure designed to evaluate medicinal products intended for markets outside the European Union.
According to a paper published in the Journal of the Royal Society of Medicine, the epidemiology behind a large scale clinical trial of an HPV vaccine, run by PATH, is flawed and the trial is currently the subject of an investigation by the Indian government.
The company attributed the problem to the levels of virus components in the end product and said the increased levels of fits must be related to characteristics of the virus unique to the 2010 strain.
PharmaThene, supported with federal funding, is developing an anti-bioterrorism anthrax vaccine, SparVax, and is planning further Phase II trials for the second half of 2012.